BibTex format
@article{Berhe:2026:cid/ciag598,
author = {Berhe, N and Desalegn, H and Mengistu, H and Birhane, D and Kebede, B and Maru, M and Girma, F and Bekele, D and Gure, T and Yaid, H and Abdi, S and Shimakawa, Y and Johannessen, A and Nayagam, S and Ndow, G and DAllessandro, U and Dibba, B and Bojang, L and Toure-Kane, C and Lo, G and Diouf, A and Faye, A and Ba, A and Hallett, T and Lemoine, M and Ward, J},
doi = {cid/ciag598},
journal = {Clinical Infectious Diseases},
title = {Effectiveness of timely hepatitis B birth dose vaccination to prevent mother-to-child transmission in Ethiopia},
url = {http://dx.doi.org/10.1093/cid/ciag598},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Mother-to-child transmission (MTCT) is an important route of new hepatitis B virus (HBV) infections. In Africa, limited and conflicting data on the effectiveness of hepatitis B birth dose vaccination (HepB-BD) have contributed to fragmented adoption and sub-optimal implementation. We aimed to assess the effectiveness of timely HepB-BD in preventing HBV MTCT in Ethiopia.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We conducted a multi-centre cross-sectional observational study in Ethiopia from May 2022 to June 2024. We identified mothers who had tested positive for hepatitis B surface antigen (HBsAg) during pregnancy and assessed mother-infant pairs at 6-12 months post-partum for HBV MTCT. We stratified effectiveness of HepB-BD by maternal risk profile (HBV DNA level, hepatitis B e-antigen (HBeAg) status).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The analysis included 387 children born to HBV-positive, HIV-negative mothers who had completed routine HBV vaccination (HepB3). The median age of infant testing was 10 months (IQR 7.0-11). Overall MTCT risk was 5.2% (95% CI 3.4,7.8). MTCT was significantly lower among infants receiving HepB-BD alone (0/39, 0% [95% CI 0-9.0]) compared to those without immunoprophylaxis at birth (20/131, 15.3% [95% CI 10.1-22.4]) (p = 0.009). No transmission occurred with HepB-BD plus HBIg (0/217, 0% [95% CI 0-1.7]). Maternal viral load >200,000 IU/ml (AOR 16.6, 95% CI 4.82,57.19) and HBeAg positivity (AOR 4.21, 95% CI 1.08,16.44) were associated with increased MTCT risk amongst infa
AU - Berhe,N
AU - Desalegn,H
AU - Mengistu,H
AU - Birhane,D
AU - Kebede,B
AU - Maru,M
AU - Girma,F
AU - Bekele,D
AU - Gure,T
AU - Yaid,H
AU - Abdi,S
AU - Shimakawa,Y
AU - Johannessen,A
AU - Nayagam,S
AU - Ndow,G
AU - DAllessandro,U
AU - Dibba,B
AU - Bojang,L
AU - Toure-Kane,C
AU - Lo,G
AU - Diouf,A
AU - Faye,A
AU - Ba,A
AU - Hallett,T
AU - Lemoine,M
AU - Ward,J
DO - cid/ciag598
PY - 2026///
SN - 1058-4838
TI - Effectiveness of timely hepatitis B birth dose vaccination to prevent mother-to-child transmission in Ethiopia
T2 - Clinical Infectious Diseases
UR - http://dx.doi.org/10.1093/cid/ciag598
UR - https://doi.org/10.1093/cid/ciag598
ER -